Clinical Trials · NCT06660173
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Amgen
- Enrollment
- 409
- Start date
- Nov 2024
- Locations
- 96 sites, 14 countries
- Primary endpoint
- Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)